Naturally Splendid Responds to Health Canada’s Information Request Notice

Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”

Naturally Splendid Closes Private Placement, Secures Laboratory Facility

— Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 15,887,503 units (the “Units”) at $0.06 per Unit, for total gross proceeds of $1,053,250 (the “Offering”). Due to oversubscribed demand, the private placement financing was increased from 14,166,667 Units to 17,554,167.Continue reading “Naturally Splendid Closes Private Placement, Secures Laboratory Facility”

Health Canada Grants No Objection Letter to Proceed with COVID-19 Phase 2 Clinical Trial

– July 29, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that the Company’s phase 2 clinical trial, as per its proposed joint venture with Biologic Pharmamedical Research for Cavaltinib(TM) (See Company news release, May 15, 2020.), has been approved for a COVID-19 clinical trial by Health Canada. The NoContinue reading “Health Canada Grants No Objection Letter to Proceed with COVID-19 Phase 2 Clinical Trial”

Health Canada Requests Clinical Trial Protocol Details

– June 30, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to provide the following update in regards to the Clinical Trial Application (CTA) to Health Canada submitted May 17, 2020 as a treatment for Covid-19 with the target drug, Cavaltinib(TM). The Company continues to navigate the fast track CTA process withContinue reading “Health Canada Requests Clinical Trial Protocol Details”